Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL).
about
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantationStem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents.Hematopoietic stem cell transplantation for the management of follicular lymphomaPromising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).Alemtuzumab in allogeneic hematopoetic stem cell transplantation.The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease.
P2860
Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Outcome following alemtuzumab ...... non-Hodgkin's lymphoma (NHL).
@en
Outcome following alemtuzumab
@nl
type
label
Outcome following alemtuzumab ...... non-Hodgkin's lymphoma (NHL).
@en
Outcome following alemtuzumab
@nl
prefLabel
Outcome following alemtuzumab ...... non-Hodgkin's lymphoma (NHL).
@en
Outcome following alemtuzumab
@nl
P1476
Outcome following alemtuzumab ...... non-Hodgkin's lymphoma (NHL).
@en
P2093
Emma Morris
Stephen Mackinnon
P356
10.1016/J.TRANSCI.2004.10.008
P577
2005-02-01T00:00:00Z